Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06360575 · FLOW

Participant flow

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) · Source last updated 2026-05-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Ineligible or Never Started
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        18
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        14
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
For subprotocol C2, patients were required to have MET Exon 14 deletion by the Oncomine® Assay RNA-sequencing approach, and confirmation was performed retrospectively at the DNA level using Anchored Multiplex PCR, utilizing a custom targeted DNA sequencing panel and analysis pipeline that permitted analysis of the MET exon 14 coding region and surrounding intronic sequences.
recruitment Details
Subprotocol C2 was activated on May 31, 2016. Twenty patients were enrolled on EAY131-C2 between July 20, 2016, and March 16, 2020. Sixteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 4 on the basis of the outside assay results.
Complete source fields
groups
  1. description
    Patients receive crizotinib 250 mg PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Treatment (Crizotinib)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      type
      Ineligible or Never Started
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        7
      type
      Disease Progression
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Withdrawal by Subject
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Physician Decision
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        18
      type
      Started Protocol Therapy
    3. achievements
      1. group Id
        FG000
        num Subjects
        14
      comment
      Primary efficacy analysis set
      type
      Eligible, Treated and Mutation Status Confirmed
    4. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      COMPLETED
    5. achievements
      1. group Id
        FG000
        num Subjects
        20
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
For subprotocol C2, patients were required to have MET Exon 14 deletion by the Oncomine® Assay RNA-sequencing approach, and confirmation was performed retrospectively at the DNA level using Anchored Multiplex PCR, utilizing a custom targeted DNA sequencing panel and analysis pipeline that permitted analysis of the MET exon 14 coding region and surrounding intronic sequences.
recruitment Details
Subprotocol C2 was activated on May 31, 2016. Twenty patients were enrolled on EAY131-C2 between July 20, 2016, and March 16, 2020. Sixteen patients were enrolled on the basis of the results from the NCI-MATCH assay and 4 on the basis of the outside assay results.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice